Improving Outcomes for Females with Bleeding Disorders in Non-Hematology Health Care Settings

Release Date: November 5, 2019
Expiration Date: October 31, 2020

Estimated Time to Complete Activity: 1.0 hour

Compatible with all modern browsers and mobile devices

Expert Faculty

	Charletta Ayers, MD, MPH Associate Professor of Obstetrics, Vice-chair of Obstetrics and Gynecology Gynecology & Reproductive Sciences Rutgers Robert Wood Johnson Medical School Click here for biography

	Gloria A Bachmann, MD Professor and Interim Chair of Obstetrics and Gynecology Associate Dean for Women's Health Director, Women's Health Institute Rutgers Robert Wood Johnson Medical School Click here for biography

	Robert F. Sidonio, Jr. MD, MSc. Associate Director of Hemostasis/Thrombosis Children’s Healthcare of Atlanta Assistant Professor, Pediatrics Emory University School of Medicine Click here for biography

Target Audience

Non-hematology specialists, registered nurses, and allied health care providers practicing in fields such as general medicine, family medicine, internal medicine, pediatrics, obstetrics/gynecology, and otolaryngology
Professionals in dental medicine and surgery, including those practicing general dentistry, orthodontics, and periodontics

Statement of Need/Program Overview
Despite an evident disease burden, many primary care physicians, specialists in areas outside of hematology, and allied health care providers lack knowledge and competence in terms of managing bleeding disorders among females. The implications are particularly noteworthy in the specialties of obstetrics/gynecology (menstruation, perinatal care), dentistry (routine procedures, extractions, etc.), and otolaryngology (epistaxis). Exacerbating a paucity of awareness and relative marginalization of females with bleeding disorders, related guidelines from the National Heart, Lung, and Blood Institute (NHLBI) and other organizations have not been updated in more than a decade, with the exception of the NHF’s Medical and Scientific Advisory Council (MASAC) recommendations. Taking this current clinical environment into consideration, further education is necessary to raise awareness, encourage collaboration with HTCs, and influence clinical practice, with the desired aim of reducing reproductive morbidity in females and improving outcomes across all patient populations.

Educational Objectives
At the conclusion of these activities, participants should be able to demonstrate improved ability to:

Evaluate symptoms associated with heavy menstrual bleeding (HMB) and diagnose bleeding disorders in females
Describe appropriate protocols for the application of diagnostic assays for bleeding disorders in females
Assess patient characteristics and history to implement management strategies for females with bleeding disorders when clinically appropriate

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the National Hemophilia Foundation, and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

DENTAL CONTINUING EDUCATION
This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint providership efforts between Postgraduate Institute for Medicine, the National Hemophilia Foundation, and Impact Education, LLC.

Postgraduate Institute for Medicine is an ADA CERP Recognized Provider.
ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry.

Concerns or complaints about a CE Provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at www.ada.org/cerp.

Postgraduate Institute for Medicine designates this activity for 1.0 continuing education credit.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Charletta Ayers, MD, MPH	No financial interest/relationships relating to the topic of this activity
Gloria A Bachmann, MD	No financial interest/relationships relating to the topic of this activity
Robert Sidonio, Jr, MD, MSc	Consulting Fees (eg, advisory boards): Biomarin, Bayer, Genentech, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Takeda, and Uniqure Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers’ bureaus): Biomarin, Sanofi Contracted Research: Genentech, Octapharma, Takeda
The PIM planners and managers have nothing to disclose. The Impact Education, LLC and National Hemophilia Foundation planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.